diaDexus, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $7,344,000 compared with $6,390,000 for the same period a year ago. This 15% increase in total Revenue was from service revenue from the first and second phases of the laboratory services contract with GSK. Loss from operations was $938,000 compared with $255,000 for the same period a year ago. Loss before income tax was $1,618,000 compared with $354,000 for the same period a year ago. Net loss was $1,619,000 or $0.03 per basic and diluted share compared with $354,000 or $0.01 for the same period a year ago.

For the nine months, the company reported total revenues of $20,455,000 compared with $18,162,000 for the same period a year ago. Loss from operations was $5,055,000 compared with $2,030,000 for the same period a year ago. Loss before income tax was $6,147,000 compared with $1,965,000 for the same period a year ago. Net loss was $6,160,000 or $0.11 per basic and diluted share compared with $1,970,000 or $0.04 per basic and diluted share for the same period a year ago.

The company provided revenue guidance for the full year of 2014. For the full year 2014, the company currently expects total revenues in the range of $26 to $28 million. This change is due primarily to the previously disclosed industry-wide impact from new, more restrictive guidance issued to cardiovascular testing facilities by the Office of the Inspector General in June 2014.